A phase 1 trial of NeoVax, a vaccine personalised from each patient's own tumour mutations, given with nivolumab in recurrent ovarian cancer found manufacturing feasible, safety acceptable and T-cell responses observed.
WhatsApp us
Sign in to your account
Remember me
